SCHEDULE: FMR LLC Discloses 15% Stake in Dianthus Therapeutics
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 15.0% in Dianthus Therapeutics Inc.'s common stock as of September 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively reported beneficial ownership of 5,970,638 shares of Dianthus Therapeutics Inc. common stock.
- This represents 15.0% of the total outstanding common stock of Dianthus Therapeutics Inc.
- FMR LLC holds sole voting power over 5,970,164 shares and sole dispositive power over 5,970,638 shares.
- Abigail P. Johnson, as Director, Chairman, and CEO of FMR LLC, is also deemed to beneficially own these shares.
- The filing states the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Several Fidelity entities, including Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, and Fidelity Management Trust Company, are identified as relevant entities, with Fidelity Management & Research Company LLC beneficially owning 5% or greater.
Sentiment
Score: 7
Explanation: The filing indicates a significant, passive institutional investment by FMR LLC, a reputable asset manager, in Dianthus Therapeutics. This suggests a positive long-term view from a major investor, although it's a standard disclosure and not an active endorsement of immediate performance.
Positives
- A significant institutional investor, FMR LLC, holds a substantial 15.0% stake, indicating potential long-term confidence in Dianthus Therapeutics Inc.
- The filing explicitly states the shares are held in the ordinary course of business and not for influencing control, suggesting a passive investment intent that may reduce concerns about activist intervention.
Risks
- The Johnson family group, through their predominant ownership of FMR LLC, may be deemed a controlling group with respect to FMR LLC, which could indirectly influence FMR LLC's investment decisions regarding Dianthus Therapeutics Inc.
Future Outlook
This Schedule 13G filing does not provide forward-looking statements or guidance regarding Dianthus Therapeutics Inc.'s future performance or FMR LLC's future investment intentions beyond the statement that the shares are held in the ordinary course of business.
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
The disclosure of a significant stake by a major institutional investor like FMR LLC in a biotechnology company such as Dianthus Therapeutics Inc. can signal institutional confidence in the company's long-term prospects, particularly in a sector known for high R&D costs and regulatory hurdles. Such investments are common as large funds seek exposure to innovative therapeutic developments.
Comparison to Industry Standards
- This filing is a disclosure of beneficial ownership and does not contain performance metrics or project results that would allow for a direct comparison to industry standards or specific comparable companies.
- The 15.0% stake is a substantial position for an institutional investor in a public company, indicating a significant commitment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure Disclosure | The filing details the ownership structure of FMR LLC, noting the Johnson family's predominant ownership of Series B voting common shares (49% voting power) and a shareholders' voting agreement, which may be deemed to form a controlling group with respect to FMR LLC. | This clarifies the ultimate control structure of the reporting entity, FMR LLC, but does not indicate changes in Dianthus Therapeutics Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by FMR LLC could be viewed positively, potentially increasing investor confidence and market liquidity.
- Company Management: The passive nature of the investment, as stated, suggests FMR LLC does not intend to influence control, allowing current management to continue their strategic direction without immediate external pressure.
Next Steps
- No specific future actions or milestones for Dianthus Therapeutics Inc. are mentioned in this beneficial ownership report.
- FMR LLC's ongoing ownership will be subject to future Schedule 13G/D amendments if their stake changes significantly.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number: -23-000003) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number: -23-000038) for Abigail P. Johnson was incorporated by reference. |
| 2025-09-30 | Date of event which requires filing of this statement (ownership snapshot date). |
| 2025-11-04 | Signature date of the Schedule 13G Amendment No. 2 filing. |
Recommendation
holdThe filing is a routine disclosure of a significant beneficial ownership stake by a major institutional investor, FMR LLC, in Dianthus Therapeutics Inc. While the 15.0% stake indicates institutional confidence, the filing explicitly states the investment is for ordinary course business and not for influencing control. This suggests a long-term, passive investment rather than an active catalyst for immediate change. Therefore, a 'hold' recommendation is appropriate as it confirms existing institutional interest without providing new information that would warrant a 'buy' or 'sell' action based solely on this filing.
Keywords
Dianthus Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.